Richmond, VA: A $94 million settlement has been reached in an antitrust lawsuit between a class of direct purchases and Pfizer, potentially ending allegations that the pharmaceutical company used fraudulent patents to delay generic competition for its anti-inflammatory drug Celebrex.
In August, a US district judge certified a class of 32 direct purchasers who alleged Pfizer cost Celebrex buyers hundreds of millions of dollars by abusing the courts and the US Patent and Trademark Office to extend its exclusive access to the drug.
On November 22, both sides filed a motion for preliminary approval of a settlement. A memorandum supporting the motion states, “The settlement assures that direct purchaser class members will receive substantial cash payments now while avoiding the uncertainties and delays of continued litigation and potential appeals.”
If approved, the settlement will end the litigation which began in 2014, and addresses issues that allegedly go back to 2008.
The case is In re Celebrex (Celecoxib) Antitrust Litigation, case number 2:14-cv-00361, in the U.S. District Court for the Eastern District of Virginia.